The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience

Table 4

Pathologic evaluation of breast tumors before and after neoadjuvant chemotherapy (n, column %).

Pathologic comparison	Before NAC n (%)	After NAC n (%)
Tumor pathology	(via tru-cut bx. of the breast)
No tumor	0 (0.0)	23 (25.0)
DCIS	0 (0.0)	3 (3.3)	NA
Infiltrating ductal carcinoma (IDC)	87 (94.6)	60 (65.2)
Infiltrating lobular carcinoma (ILC)	3 (3.3)	2 (2.2)
Other	2 (2.2)	4 (4.3)
ER			McNemar
Negative	22 (23.9)	12 (13.0)
Positive	66 (71.7)	57(62.0)
Unavailable	4 (4.3)	23 (25.0)
Mean (%) ± SD	76.53 ± 21.85	80.57 ± 23.99	Mean
PR			McNemar
Negative	25 (27.2)	20 (21.7)
Positive	64 (69.6)	48 (52.2)
Unavailable	3 (3.3)	24 (26.1)
Mean (%) ± SD	63.05 ± 32.40	55.05 ± 31.87	Mean
CerbB2
Negative	63 (68.5)	51 (55.4)	McNemar
Positive	29 (31.5)	16 (17.4)
Unavailable	0 (0)	25 (27.2)
Ki67
Mean (%) ± SD	25.75 ± 15.16	20.36 ± 13.68	0.024
P53
Mean (%) ± SD	35.83 ± 38.27	37.50 ± 39.12	<0.001
Histologic grade
1		5 (5.4)
2		37 (40.2)
3		16 (17.4)
Nuclear grade
1		3 (3.3)
2		28 (30.4)
3		25 (27.2)
Lymphovascular invasion
Absent		58 (63)
Present		11 (12)